Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.59% | -335.93% | -351.04% | -328.36% | -318.68% |
| Total Depreciation and Amortization | -32.59% | -28.64% | -27.12% | -26.88% | -25.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.50% | 27.03% | -13.21% | -25.13% | -5.69% |
| Change in Net Operating Assets | 34.47% | -667.09% | -49.24% | 80.61% | -578.39% |
| Cash from Operations | -1.25% | -273.93% | -247.38% | -237.16% | -229.91% |
| Capital Expenditure | 78.43% | 49.61% | 30.78% | -136.98% | -197.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -20,792.93% | -13,986.38% | -14,805.14% | -11,736.81% | -197.87% |
| Total Debt Issued | -- | 15,112.74% | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 128.44% | 20.46% | 37,865.21% | 40,187.10% | 28,181.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 65.53% | 2.27% | 6.53% | -38.36% | -3,116.30% |
| Cash from Financing | 71.92% | -2.72% | 196.55% | 782.08% | 379.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.18% | -136.17% | -104.51% | 44.16% | -26.33% |